Biocar Pharmaceutical Co.,Ltd. 
Appearance: White PowderCAS: 21187-98-4Storage: Cool Dry PlaceDeliver Time: 7-10 DaysSelf Life: 2 YearsBrand: BIOCAR
Product Detail
Wholesales 99% High Quality Original Powder Gliclazide CAS21187-98-4 with Safe Delivery
Basic Information
| Name: | Gliclazide |
| Purity: | 99% |
| Cas no.: | 21187-98-4 |
| Appearance: | White Powder |
| Supply Ability : | 2Mt/Per Month |
| Storage: | Store in a well-closed container away from moisture |
Description
Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life. Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).Function
1.Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non-ketosis prone, type 2 diabetes. It is used when diabetes cannot be controlled by proper dietary management and exercise or when insulin therapy is not appropriate. National Kidney Foundation (2012 Update) claims that Gliclazide does not require dosage uptitration even in end stage kidney disease.
2.Fall blood sugar medicine, used in the treatment of non insulin dependent diabetes
3.It is mainly used for adult onset diet alone invalid, and no diabetes ketosis tendency of light duty.
4.Also improve diabetics fundus diseases and metabolic disorder of blood vessel function.
1. For adults with type 2 diabetes, diabetes associated with obesity or vascular lesions.
2. Hypoglycemic agents. It can be used for the treatment of non-insulin dependent diabetes mellitus.
3. Hypoglycemic agents, non-insulin dependent diabetes mellitus.
COA
| Items | Standard of quality | Results of analysis |
| Characteristics | A white or almost white powder | A white powder |
| Solubility | Practically insoluble in water;freely soluble in dichloromethane;sparingly soluble in acetone;slightly soluble in alcohol. | Meets the requirements |
| Identification | The infrared absorption spectrum is concordant with the reference spectrum | Meets the requirements |
| Impurity B | ≤2ppm | 0.1ppm |
| Related substances | Impurity F ≤0.15% | Non-detected |
| Other individual impurity≤0.10% | 0.03& | |
| Total unknown impurity≤0.20% | 0.05% | |
| Loss on drying | ≤0.25% | 0.2% |
| Sulphated ash | ≤0.1% | 0.03% |
| Residual Solvents | Ethyl acetate NMT 2500ppm | 175ppm |
| Toluene NMT 890 ppm | Non-detected | |
| Ethanol NMT 5000ppm | Non-detected | |
| THF NMT 720ppm | Non-detected | |
| Assay | 99.0%-101.0% | 99.7% |
